Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Safety and Thrombolytic Effects of Ascending Doses of TS23 in Subjects With Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism

Trial Profile

Evaluation of the Safety and Thrombolytic Effects of Ascending Doses of TS23 in Subjects With Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TS 23 (Primary)
  • Indications Pulmonary embolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NAIL-IT
  • Sponsors Translational Sciences

Most Recent Events

  • 06 Jul 2026 Planned number of patients changed from 32 to 64.
  • 01 Jul 2026 Planned End Date changed from 1 Sep 2024 to 1 Nov 2026.
  • 01 Jul 2026 Planned primary completion date changed from 1 Jul 2024 to 31 Aug 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top